Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
BAUSCH HEALTH IRELAND LIMITED currently has 2 pending office actions. These actions are within the Biotechnology & Pharmaceuticals technology area. The 2 pending office actions are assigned to 2 distinct examiners, meaning each case is being handled by a different person. Additionally, these matters are spread across distinct art units, indicating that the pending applications fall into different pharmaceutical or biotechnological classifications. This distribution suggests a range of technical subject matter within the current pending portfolio.
Patel, Ronak C is the busiest examiner for this portfolio, with 1 pending office action. Since there are distinct examiners for the pending office actions, each examiner holds a portion of the workload. This distribution across the 2 distinct art units and the distinct examiners means there is no overlap in the current pending workload. Practitioners must manage separate examiner relationships and different art unit environments simultaneously. The 2 pending office actions represent the company's current active engagement with the patent office in the Biotechnology & Pharmaceuticals sector. Each of the distinct examiners will offer an independent review of the pending technology.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PATEL, RONAK C | 1 | 51.2% | +56.4% |
| SIMMONS, CHRIS E | 1 | 34.1% | +19.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18935127 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | PATEL, RONAK C | — |
| 17529818 | USE OF METHYLNALTREXONE AND RIFAXIMIN FOR TREATMENT OF INCREASED GUT PERMEABILITY OR ASSOCIATED DISORDERS | SIMMONS, CHRIS E | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18935127 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | PATEL, RONAK C | 1658 | §102DPOther | Non-Final OA | — | Pending | Nov 01, 2024 |
| 17529818 | USE OF METHYLNALTREXONE AND RIFAXIMIN FOR TREATMENT OF INCREASED GUT PERMEABILITY OR ASSOCIATED DISORDERS | SIMMONS, CHRIS E | 1622 | §103 | Non-Final OA | — | Pending | Nov 18, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial